Last reviewed · How we verify
NCT07209358
EDX110 Randomized Control Trial for Treatment of DFUs
NA trial testing EDX110 in Wound Heal in 298 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | ConvaTec Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 298 |
| Start date | 30 October 2025 |
| Primary completion | 1 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- EDX110
Conditions studied
- Wound Heal — all drugs for Wound Heal →
- Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →
Sponsor
ConvaTec Inc.
Who can join
Adults 18 to 90, any sex, with Wound Heal or Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07209358
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Wound Heal
Currently open trials in the same condition.
- NCT07261501 — An Exploratory Research on the Efficacy and Safety of Antibacterial Absorbable Dressing in Chronic Non-healing Wounds · NA · recruiting
- NCT06522438 — Hyaluronic Acid and Octenidine Gel as an Adjunct to Non-surgical Periodontal Treatment · NA · recruiting
- NCT06841237 — Randomized Controlled Trial on the Efficacy and Safety of Xiang Lei Ointment in Diabetic-related Ulcer Management · NA · recruiting
- NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Phase 2 · recruiting
- NCT06337292 — Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures · Phase 3 · recruiting
Other ConvaTec Inc. trials
Trials by the same sponsor.
- NCT07342049 — ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds · NA · not yet recruiting
- NCT07308678 — AQUACEL® Ag+ Extra™ vs Cutimed® Sorbact® · completed
- NCT06614491 — SCOPE - Single-Point Classification Observational Peristomal Evaluation · completed
- NCT07170566 — A Retrospective, Observational Study of the Real-world Safety and Performance of InnovaMatrix® AC at a Single Centre · completed
- NCT05805046 — Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07209358 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ConvaTec Inc.
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07209358.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing